New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For QGEN From The Last 14 Days
Check below for free stories on QGEN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2014
16:14 EDTQGENQIAGEN sees Q3 adjusted EPS 26c-27c, consensus 27c
Sees Q3 adjusted net sales up 4%-5% CER.
16:13 EDTQGENQIAGEN reaffirms 2014 EPS outlook $1.07-1.09, consensus $1.09
Subscribe for More Information
16:12 EDTQGENQIAGEN announces new $100M share repurchase program
QIAGEN announced today the launch of its third $100M share repurchase program after completing its second $100M program in June. In the second repurchase program, approximately 4.5M shares were repurchased on the Frankfurt Stock Exchange.
16:12 EDTQGENQIAGEN reports Q2 adjusted EPS 26c, consensus 25c
Reports Q2 revenue $331.2M, consensus $330.8M.
July 28, 2014
05:36 EDTQGENQIAGEN, AstraZeneca announce collaboration
QIAGEN (QGEN) announced a collaboration agreement with AstraZeneca (AZN) for the co-development and commercialization of a liquid biopsy-based companion diagnostic to be paired with IRESSA, AstraZeneca's targeted therapy for non-small cell lung cancer, or NSCLC. The project builds on a master framework agreement signed by both companies in 2013 and aims to develop and market a novel QIAGEN companion diagnostic that analyzes plasma samples to assess EGFR mutation status in NSCLC patients. The assay will be designed to guide the treatment of NSCLC patients with Astra Zeneca's oral monotherapy anti-cancer treatment when tumor tissue is not available. QIAGEN already offers the therascreen EGFR RGQ PCR Kit as a tissue-based companion diagnostic for lung cancer patients, which was approved in the U.S. by the FDA in July 2013 and in China in May 2014. The companies will collaborate to create a new companion diagnostic for IRESSA based on liquid biopsy samples from NSCLC patients, rather than requiring invasive surgical collection of tissue samples. Data from several studies, including the IFUM Study presented at the "World Lung 2013" conference, provided evidence of the ability to assess the EGFR status of advanced lung cancer patients using blood / plasma samples. This breakthrough provides hope for patients for whom surgical biopsy is not an option by enabling them to have their EGFR mutation status assessed using a less invasive method.
July 24, 2014
16:17 EDTQGENQIAGEN acquires exclusive global license to the biomarker SF3B1
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use